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CaliforniaABSTRACT The blood-brain barrier (BBB) is formed by specialized tight junctions between endothelial cells that line brain
capillaries to create a highly selective barrier between the brain and the rest of the body. A major problem to overcome in
drug design is the ability of the compound in question to cross the BBB. Neuroactive drugs are required to cross the BBB to
function. Conversely, drugs that target other parts of the body ideally should not cross the BBB to avoid possible psychotropic
side effects. Thus, the task of predicting the BBB permeability of new compounds is of great importance. Two gold-standard
experimental measures of BBB permeability are logBB (the concentration of drug in the brain divided by concentration in the
blood) and logPS (permeability surface-area product). Both methods are time-consuming and expensive, and although logPS
is considered the more informative measure, it is lower throughput and more resource intensive. With continual increases in
computer power and improvements in molecular simulations, in silico methods may provide viable alternatives. Computational
predictions of these two parameters for a sample of 12 small molecule compounds were performed. The potential of mean force
for each compound through a 1,2-dioleoyl-sn-glycero-3-phosphocholine bilayer is determined by molecular dynamics simula-
tions. This system setup is often used as a simple BBB mimetic. Additionally, one-dimensional position-dependent diffusion
coefficients are calculated from the molecular dynamics trajectories. The diffusion coefficient is combined with the free energy
landscape to calculate the effective permeability (Peff) for each sample compound. The relative values of these permeabilities
are compared to experimentally determined logBB and logPS values. Our computational predictions correlate remarkably well
with both logBB (R2 ¼ 0.94) and logPS (R2 ¼ 0.90). Thus, we have demonstrated that this approach may have the potential to
provide reliable, quantitatively predictive BBB permeability, using a relatively quick, inexpensive method.INTRODUCTIONMost drugs need to pass through at least one cellular mem-
brane to reach their intended target. Although tight binding
of a drug molecule to its intended target is important for
potency, poor membrane permeability will likely result in
a lack of efficacy in vivo. Thus, a detailed understanding
of the partitioning of the solute in the membrane is vitally
important for pharmacokinetics and rational drug design.
Two possible transport modes are available for a molecule
to pass through a membrane: active and passive (1). Active
transport involves a transport protein that uses energy, e.g.,
ATP hydrolysis, to shuttle a molecule across a membrane.
Passive transport, however, is the most common mode of
drug passage through membranes and involves diffusion
with no outside assistance or energy consumption. The
rate of passive diffusion across a membrane is proportional
to the partition coefficient of the compound between the
membrane and the external medium, the diffusion coeffi-
cient of the compound through the membrane, and the com-
pound’s concentration gradient across the membrane (2).
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0006-3495/14/08/0630/12 $2.00process of membrane binding and diffusion are lipophilicity,
molecular weight, and measures of molecular polarity (3).
Drugs that specifically target the central nervous system
(CNS) must first pass the blood-brain barrier (BBB). Con-
sisting of endothelial cells that form the brain capillaries
(4), the BBB restricts the penetration of molecules, because
of tight junctions formed by lateral transmembrane proteins,
lack of fenestrations, the negative surface polarity, and the
high level of efflux transporters, especially P-glycoprotein
(P-gp) (5). The tight junctions significantly reduce perme-
ation of ions and other small hydrophilic solutes through
the intercellular cleft (paracellular pathway), thus forming
the physical barrier. Essential molecular fluxes must use
predominantly transcellular pathways. Passive diffusion
of small compounds is assumed to be the most important
permeability process through the BBB, although active
transport of compounds may be more significant than orig-
inally thought (6). Although the BBB is protective in nature,
the inability for drug molecules to permeate the BBB is a
significant impediment for CNS drug candidates and
should be addressed early in the drug discovery process
(7). Additionally, drugs targeting peripheral organs need
to be investigated for BBB permeability to avoid possible
CNS side effects.http://dx.doi.org/10.1016/j.bpj.2014.06.024
Prediction of BBB Permeability 631Based upon the large assumption that a compound’s
activity is equivalent to its BBB permeability, compounds
are often classified by the terms CNSþ or CNS. (8–10)
CNSþ refers to compounds that show a desired in vivo
effect in the CNS, whereas CNS refers to compounds
that do not show an expected in vivo CNS effect. However,
this descriptor is phenotypic and does not properly describe
those compounds that have low BBB permeability but high
potency. Thus, this descriptor can be misleading.
Perhaps the most common parameter used to quantify
penetration of a compound across the BBB is the ratio of
the concentration of compound measured in the brain to
the concentration of compound measured in the blood at
steady state. This ratio is expressed as logBB (log[brain]/
[blood]) and determines the total extent of brain exposure,
at a steady state.
A less commonly used descriptor of BBB permeability is
the determination of the permeability surface-area product
(expressed as logPS). LogPS is perhaps a more appropriate
in vivo measurement when considering BBB penetration
(11,12) and is more informative than logBB. The logPS
measurement is most often performed following the perfu-
sion method that was implemented by Takasato et al. (13).
In doing this, the method eliminates the effect of serum
binding of the compound in question and provides a direct
measure of BBB apparent permeability. However, because
of the need for microsurgical expertise, the logPS measure-
ment is resource intensive and relatively low throughput. As
a result, significantly less literature data are available. PS
can be calculated using the Renkin-Crone (14,15) equation:
PS ¼ F ln

1 Kin
F

; (1)
where PS (the permeability surface-area product) is
measured in (ml/min/g brain), F is the cerebral blood or
perfusion flow rate (ml/min/g brain), and Kin is the unidirec-
tional transfer constant. Kin is equal to (Qbr/Cpf)/T, where
Qbr is the concentration of compound in the brain (corrected
for the vascular volume), Cpf is the concentration of
compound in the perfusion fluid, and T is the perfusion
time. Note, logBB measures concentrations at equilibrium,
whereas logPS is more a measurement of the initial perme-
ability rate. As such, logPS is the pharmacokinetic uptake
clearance across the BBB into the brain.
Because of the labor-intensive, expensive, low-throughput,
and technically challenging process of obtaining detailed
in vivo BBB permeability data, several well-characterized
in vitro and in silico permeability prediction methods have
been developed. These methods are faster, cheaper, easier
to carry out, and are important in the early stages of the
drug discovery process.
Two of the most common and relatively simple in vitro
BBB permeability prediction methods are the parallel artifi-
cial membrane permeability assay (PAMPA) and the immo-
bilized artificial membrane (IAM) technique. The PAMPAin vitro technique was developed in 1998 by Kansy, et al.
(16). It was originally developed to rapidly predict passive
permeability through the gastrointestinal tract, but has since
been adapted for use in BBB studies by Di, et al. (17).
PAMPA-BBB has shown good prediction of BBB penetra-
tion for CNS classes of drugs (17–22). The technique in-
volves a donor compartment and an acceptor compartment
separated by a filter supporting a liquid artificial membrane.
The artificial membrane can be composed of a variety of
phospholipid mixtures. The compound to be tested is placed
in the donor compartment and is allowed to permeate be-
tween the donor and the acceptor compartments through
the artificial membrane. As the assay can be performed in
96-well plates, high throughput screening is possible.
IAMs mimic the phospholipid environment of the BBB by
anchoring synthetic lipid analogs to silica particles in mono-
layer density. These particles are then used as the packing
material for a high-performance liquid chromatography col-
umn (23–26). The IAM chromatographic retention factors
are used to generate predictions of membrane permeability.
These systems have shown reasonable results for prediction
of permeability, despite the retention time in the column not
reflecting actual passage across the membrane (27,28).
An alternate approach is to employ computational
methods to compute logBB. Most in silico prediction ap-
proaches use quantitative structure-activity relationship
(QSAR) models (29–33). In QSAR studies, the biological
activity is treated as an outcome of the various interactions
that a compound experiences during transport through BBB
(whether this be passive or active). These interactions are
assumed to be governed by the chemical structure and prop-
erties of the compound, also known as descriptors. As such a
mathematical model of the biological activity is optimized
based on a combination of a variety of descriptors for the
small molecule compound. Thus, a change in structure
can result in a change in biological response, which in this
case is permeability through the BBB.
One of the most powerful (though computer intensive)
in silico techniques is molecular dynamics (MD), which
allows the simulation of molecular processes, such as diffu-
sion, at the atomic level (34). Coupling MD with free energy
techniques provides a powerful tool to study membrane
permeability in detail (35). Human membranes are a com-
plicated mixture of small molecules, various lipids, and
proteins, but with a judicious choice of lipid a single bilayer
may provide similar physicochemical properties to a
cellular membrane. Indeed, phosphatidylcholine lipids are
the major phospholipid within cellular membranes (36).
Previous studies have investigated the permeation of small
molecules (such as water and ethanol) and a limited number
of drug molecules through homogenous lipid bilayers
(37–42). Although these MD simulations could not replicate
the same absolute permeability values seen experimentally,
they were able to reproduce the relative permeabilities of
these compounds.Biophysical Journal 107(3) 630–641
632 Carpenter et al.In this study, we use free-energy simulations to in-
vestigate the permeability of 12 diverse small molecule
compounds (Fig. 1) through a simple BBB mimic. We com-
pare the computed effective permeabilities (Peff) of these
compounds to experimentally measured values of logBB
and logPS and find this approach to be reliable and predic-
tive of compound permeability through the BBB.METHODS
For this study, the following small molecule compounds were chosen: al-
prazolam, atenolol, chlorpromazine, cimetidine, ibuprofen, imipramine,
mannitol, nordazepam, promazine, salbutamol, salicylate, and theophylline
(Fig. 1). The sample set was selected based upon several criteria, such as
their size, charge, general ability to cross the BBB via a passive diffusion
mechanism, and most are compounds that have been used in previous
BBB permeability studies. Of importance, they cover a wide range of logBB
values from ~1.5 to 2.5 as evenly distributed as possible (Table 1, see
Fig. 3 A). Of the 12 compounds, six are identified in the literature (43–46)
to cross the BBB, and six are identified to not cross the BBB (Table 1).MD setup
All simulations were run using GROMACS 4.5.5 (47). The Berger, et al.
force field was used for the 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC) molecules (48), the gromos53a6 force field was used for the small
compounds (49), and the SPC model was used to represent the water (50).
Each simulation contained a single copy of the compound harmonically
restrained at specified locations along the z axis in the solvated DOPC
bilayer system. The complete system contained 5124 water molecules, 72
DOPC molecules, and one small compound. A typical system containedFIGURE 1 Molecular structure of t
Biophysical Journal 107(3) 630–641a total of ~19,300 atoms. The system was energy minimized using a
combination of steepest descents and conjugate gradients.
The energy-minimized system was used for MD simulations. Simula-
tions were performed at 323 K (well above the gel-liquid phase transition
temperature) using the Nose´-Hoover thermostat (51) with tT ¼ 0.5 ps.
The pressure was maintained at 1 bar using a semi-isotropic Parrinello-Rah-
man barostat (52) with tP¼ 1 ps and a compressibility of 4.5 105 bar1.
Bond lengths were constrained using the LINCS algorithm (53), allowing a
2 fs time step to be used. Nonbonded interactions were truncated at 1.4 nm,
and the neighbor list updated every 10 ps. The long-range electrostatic in-
teractions were calculated using the particle mesh Ewald method (54,55).
The topologies for the small molecule compounds were generated using
the Automated Topology Builder server [http://compbio.chemistry.uq.edu.
au/atb/] (56). The topology-building server combines a knowledge-based
approach with quantum mechanical calculations to produce parameters
that are compatible with the desired force field. Initially, the molecule is
optimized at the HF/STO-3G level of theory, and then reoptimized at the
B3LYP/6-31G* level of theory (57–59) in implicit water. The charges are
initially estimated by fitting the electrostatic potential using a Kollman-
Singh scheme (60). The Hessian matrix is then calculated and used to esti-
mate force constants for bonds and angles. All compounds were modeled in
their neutral forms and physiologically relevant charged states. All param-
eters are freely available from the Automated Topology Builder server.Free-energy calculations
Umbrella sampling was used to calculate the potential of mean force (PMF)
free-energy profiles for the partitioning of compounds. A single harmonic
restraint with a force constant of 1000 kJ mol1 nm2 was applied to the
distance between the center of mass of the DOPC bilayer and the center
of mass of the compound, in the direction of the z axis (the normal to the
bilayer). One hundred different umbrella sampling simulations were per-
formed in increments of 0.1 nm along the z axis direction. The center ofhe 12 small compounds studied.
TABLE 1 List of molecules investigated and their BBB permeability parameters
Compound logBB logPS Calculated logPeff BBBþ/ aPredicted BBBþ/ bPredicted logBB References
Mannitol 2.51 4.30 6.62   2.30 (46,70,71)
Cimetidine 1.42 3.93 3.94   1.34 (20,43,72)
Salicylate 1.10 3.40 5.17   1.78 (29,45,73)
Salbutamol 1.03 c 1.95   1.31 (43,74)
Atenolol 0.87 c 1.77   0.57 (43,75)
Theophylline 0.29 2.80 0.94   0.27 (44,71,73)
Ibuprofen 0.18 1.58 0.63 D  0.16 (45,75,76)
Alprazolam 0.02 c 0.67 D D 0.30 (43,75)
Nordazepam 0.50 1.00 2.04 D D 0.79 (43,77,78)
Imipramine 0.83 1.43 2.13 D D 0.82 (43,79,80)
Chlorpromazine 1.06 1.20 2.68 D D 1.02 (43,73,81)
Promazine 1.23 c 2.78 D D 1.05 (43,82)
aPredicted BBBþ if logPeffR 0, predicted BBB if logPeff < 0.
bUsing Eq. 7.
cNo data available.
Prediction of BBB Permeability 633the bilayer was treated as z¼ 0, thus the windows spanned z¼5 nm to z¼
5 nm. The 10 nm distance completely covers the traversal of the compound
from bulk water, through the entire membrane, and out into bulk water
again. This set of simulations was carried out for each of the compounds
of interest, as well as ethanol (a threonine side-chain analog), which was
used as a control for comparison to previously published data (41).
Each simulation windowwas initially run for ~45 ns, for a total of ~100 ms
of simulation time for the 20 different drug compounds charged state
combinations and one control simulation. The initial ~20 ns of each simula-
tion was regarded as extensive equilibration time to allow the compound to
correctly orient within the system. This equilibration timewas tested to see if
the PMF curves for each compound had converged (Fig. S1 in the Supporting
Material). If needed, simulations were extended or the number of umbrella
sampling windows were increased to achieve convergence. All subsequent
analyses were carried out only on the final 25 ns of each simulation.
The weighted histogram analysis method (61), as implemented within
GROMACS, was used to calculate the PMF for each compound based
upon the data from the umbrella sampling distributions. The PMF curves
are averaged as the distance of the compound from the center of the bilayer
(where z ¼ 0) because the lipid bilayer can be treated as symmetrical. All
free-energy profiles are normalized to zero in bulk water.Diffusion and permeability
Membrane permeability of a small molecule can be calculated by
combining information from the PMF 1D energy landscape with diffusion
coefficients within the membrane. These diffusion rates may vary with
position within the membrane.
The position-specific diffusion coefficients were calculated from the MD
simulation data using the method of Hummer (62). For each position-
restrained simulation, the positions of the compound were sampled at
2 ps intervals, and the variance and autocovariance—at lags from one inter-
val up to 500 intervals—were calculated using 500 points for each variance
or covariance calculation. The resulting autocovariance curve decays
roughly exponentially with increasing lag time—though experimental noise
causes the curve to fluctuate around zero rather than decaying fully to zero
with increasing lag. A least-squares fit to the log of the autocovariance data
was made to estimate the characteristic time, t, of the autocovariance decay.
The long-run fluctuations around zero were not included in this estimate—
points on the curve after it first decays within the standard deviation of the
long-run fluctuations were discarded. The diffusion coefficient was calcu-
lated as
DðZÞ ¼ varðZÞ
tZ
; (2)where hZi is the average of the reaction coordinate Z in the biased run, and
varðzÞ is the variance of the compound position (the auto-covariance at lag
zero). The autocovariance curve/diffusion calculation was repeated at
500-sample-point intervals for the duration of the MD simulation, thus
providing ~40 largely independent estimates of the diffusion coefficient
for each position-restrained MD simulation. These estimates were averaged
to produce the position-specific diffusion coefficient.
The effective membrane permeability, Peff, can be calculated from the
integral for effective resistivity, Reff, (Marrink and Berendsen (63)),
1
Peff
¼ Reff ¼
Z Z
0
RðzÞdz (3)
where R(z) is the resistivity of each membrane slice,
bðDGðzÞÞ
RðzÞ ¼ e
DðzÞ ; (4)
where b is 1/(kBT), that is, the inverse of the Boltzmann constant times the
temperature, DG(z) is the free energy from the PMF calculations, and theintegral is over the bounds of the membrane.
In cases where a compound can exist in two protonation states at pH 7.4
(representation of physiological blood (64) and cytoplasmic (65) pH), the
position-specific diffusion coefficient calculations are then carried out sepa-
rately for each form—charged and neutral. In these cases the calculation of
the resistivity of each membrane slice takes into account the potential flux
of each form, accounting for the free-energy difference between the
charged and neutral forms at each position,
RðzÞ ¼ RcðzÞRnðzÞ
RcðzÞ þ RnðzÞ; (5)
where Rc(z) and Rn(z), are the resistivity of the charged and neutral forms,
respectively. Rc(z) is calculated as in Eq. 3, with DGc(z), the free energy ofthe charged form at position z compared to its free energy in bulk water, re-
placing DG(z). Rn(z) is calculated analogously, except that the neutral spe-
cies PMFs used to calculate DGn(z) have been offset by the free energy
required to neutralize the charged species of that compound in bulk water
at pH 7.4, according to the method described by MacCallum, Bennett,
and Tieleman (41),
DGneutralize ¼ ðpKa  pHÞRT ln10; (6)
where the pKa for a compound is obtained from the literature, R is the
gas constant, T is the temperature, and the pH is the physiological valueof 7.4.Biophysical Journal 107(3) 630–641
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In silico system is consistent with existing
published data
Membranes can have complicated phase behavior and care
must be taken to simulate the desired phase. To ensure
that the DOPC bilayer has the correct fluidity, the partial
density profile of the system (Fig. 2 A) was measured to
ensure the correct conformation of the bilayer and was
compared to previous simulations (41,66–68). The density
profile agrees extremely well with the published data, indi-
cating that the system is equilibrated and behaving as antic-
ipated. The membrane thickness (just>4 nm) lies within the
limits defined by those previous simulations. The area per
lipid is slightly (0.02–0.03 nm2) smaller than previous
studies. However, this value is self-consistent (standard
deviation of 0.01–0.02 nm2), and is only just outside the
experimental range of uncertainty (0.01 nm2). The mem-
brane-solvent interface is at ~2.5–3.0 nm from the center
of the bilayer. Additionally, there is the characteristic dip
in the density at the center of the bilayer due to the disorder
of the lipid tails.
A second validation measure was to carry out a free-
energy control simulation on a highly studied molecule-3.0 -2.0 -1.0 3.02.01.00.0
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FIGURE 2 (A) Transverse partial density profile of the various compo-
nents of the DOPC lipids forming the membrane. (B) PMF free energy
for ethanol traversing through the DOPC membrane.
Biophysical Journal 107(3) 630–641(ethanol) to ensure the generated parameters for the drug
molecules are compatible with the GROMACS force field.
For this simple test, we calculated the PMF profile for
ethanol (Fig. 2 B), permeating the DOPC membrane. This
small, uncomplicated molecule was previously studied by
MacCallum, et al. (41,67), using the same lipid and water
models, as the side-chain analog to threonine. The shape
of our ethanol PMF curve is almost identical to that cal-
culated by MacCallum, et al. A small maxima occurs at
~2.0 nm from the bilayer center (hydrophilic portion of
the bilayer). There is a single minima at ~1.3 nm from the
bilayer center due to the amphipathic nature of this region.
A maximum plateau occurs at ~0.5 nm from the hydropho-
bic bilayer center. Indeed, our calculated free energy at the
bilayer center (2.9 kcal/mol) is very similar to the reported
3.1 kcal/mol (41), and our calculated free energy at the
interface (0.9 kcal/mol) is also very close to the previously
reported value of 1.0 kcal/mol (67). In the study by Mac-
Callum et al., parameters for ethanol were derived from the
OPLS force field, which has been shown to be well suited
for free-energy calculations. The ethanol parameters gener-
ated from the ATB server perform as well as OPLS and
should also provide reliable simulation results for the sam-
ple set of small molecule compounds.
Despite this excellent agreement with published data, our
ethanol simulation was only carried out as a comparative
control measure and will not be used for the BBB perme-
ability analysis because ethanol is a notoriously difficult
compound to measure (Liu, et al. (29) report an eightfold
error in predicting ethanol logPS). Ethanol does not behave
in the same way as other small drugs (29), and furthermore
may itself alter the integrity of the BBB (69).Free-energy calculations for compounds
crossing the bilayer
PMF profiles for the 12 compounds were calculated
(Fig. 3 B). In general, the PMFs for most of these compounds
show qualitatively similar overall behavior, but differ quan-
titatively within the membrane. All the compounds show an
initial stabilizing interaction (the range of which varies from
~0.5–3.0 kcal/mol) when first going from bulk solvent into
the headgroup region of the membrane (~2.5–3.0 nm from
the bilayer center). Generally, the most stabilizing region
of the membrane is 1.0–1.5 nm from the center of the mem-
brane (with the exceptions of mannitol and salicylate, which
are most stabilized at ~2.0–2.5 nm). This typical stabiliza-
tion at ~1.0–1.5 nm from the center of the membrane reflects
the amphipathic nature of these compounds because they
must be soluble enough to travel in blood yet be hydrophobic
enough to penetrate cellular membranes. A relative barrier
(compared to the minima) for every compound is at the
membrane center.
A general observation can be made about the PMF curves
in terms of how they relate to the BBB permeability of the
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(B) The PMFs for the molecules studied. For com-
pounds that exist primarily as charged species at
physiological pH, PMFs for both the charged and
neutral state were calculated (Fig. S2). Their com-
bined PMFs are presented here. BBBþ compounds
are colored dark blue to green, whereas BBB
compounds are colored dark red to yellow.
Prediction of BBB Permeability 635compounds. The PMFs of BBBþ compounds are typically
more negative relative to the free energy in bulk solvent,
with the free energy at z ¼ 0 also negative (or just slightly
above zero). In contrast, the PMFs of BBB compounds
are more positive, with the free energy at z ¼ 0 always pos-
itive relative to the free energy in bulk solvent.
The position-dependent diffusion coefficients for these
compounds do not vary significantly from one another
(Fig. 4). The average diffusion within the region of the
bilayer (z < 3.0 nm) for the compounds range from ~0.7 
106 cm2/s to ~1.4  106 cm2/s. Throughout the bilayer,
the values for each compound reach their minimum plateau
at zz 2.5–3.0, tending to be slightly higher at the disordered
center. All the compounds show an order of magnitude in-
crease in diffusion in bulk solvent relative to their calculated
values within the bilayer. This is consistent with previous
constrained MD simulations for small molecule compounds
and drugs passing through a lipid bilayer. Our calculated
diffusion coefficient for theophylline in bulk solvent
(measured when z > 4.0 nm) is 1.4  105 cm2/s. This is
approximately a factor of two higher than published data0 1 2 3
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FIGURE 4 The calculated diffusion profiles for the compounds from
bulk water through to the bilayer center. The average diffusion values
(for z < 3.0 nm) of the compounds are not significantly different and
show no correlation with the logBB for that compound (inset).(83,84), but is consistent with the calculated self-diffusion
of the SPC model of water that is also a factor of two higher
than experimental values (85). However, these isolated
membrane diffusion coefficients have no correlation with
the experimental permeability values (Fig. 4, inset). Thus,
in agreement with published data (38,86), the energy land-
scape of the compound appears to be the largest contribution
to its permeability.Computed Peff values have high correlation with
experimental permeation measurements
Our goal is to assess the ability of our simple BBB mimetic
system to reproduce the experimentally determined BBB
permeability of these compounds. This assessment is first
carried out in a qualitative fashion, to determine if we could
correctly identify a compound as either BBBþ (crosses the
BBB) or BBB (does not cross the BBB). Subsequently, we
subject our results to a more quantitative comparison, to
establish how our relative permeability measurements corre-
lated with experimental data.
Classification schemes reported in the literature use
slightly different logBB cutoffs to classify compounds as
either BBBþ or BBB. These values range from 1.00
(87) to þ0.63 (9). However, a large number of these classi-
fication schemes report the cutoff criteria to be a logBB
value of 0.00, with compounds that have a logBBR0.00 be-
ing BBBþ (43,88–90). Notably, a logBB of zero implies an
equal concentration on both sides of the BBB. Ibuprofen is a
well-documented example that violates the cut-off rule,
albeit by a small amount. Although ibuprofen is a BBBþ
compound (45), it actually has a logBB of 0.18 (75),
slightly below the cutoff. The equivalent cutoff value for
logPS (though not as robustly studied) is about 2.00,
with compounds that have a logPS R 2.00 being BBBþ
(91). The range of logPeff values calculated for our sample
set of 12 compounds is from ~2.8 to 6.6, a range of nearly
10 log units (Table 1).
The logPeff data is plotted against the corresponding
logBB and logPS values, and the linear regression line for
data is calculated (Fig. 5). The linear regression plotsBiophysical Journal 107(3) 630–641
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636 Carpenter et al.show that when the logBB or logPS values are at their
respective cut-off thresholds (0.00 and 2.00), the corre-
sponding logPeff value is then ~0.00. This is true for both
the logBB and the logPS plots. Thus, logPeff ¼ 0.00 is cho-
sen as the cut-off for determining BBBþ/ in our model.
Using this value of logPeff ¼ 0.00 as the BBBþ/ cutoff,
our analysis and calculations correctly classifies 11 of
the 12 compounds into the appropriate BBBþ/ category
(Table 1). The only compound incorrectly classified was
ibuprofen. Even this incorrect classification was somewhat
encouraging, as ibuprofen falls into the blurred region at
the interface of BBBþ/ classification. Indeed, it was
very close (~0.6) to the cutoff value.
As a further qualitative assessment metric, the relative
order of the compounds (in terms of their permeability)
is also assessed. Of the 12 compounds, 10 are in the correct
relative order when comparing our calculated logPeff values
to the experimentally measured logBB values. The only
two compounds that are ranked incorrectly are cimetidine
and salicylate. The order of these two compounds isBiophysical Journal 107(3) 630–641switched, with the logPeff of the two being about one log
unit apart.
From a quantitative point of view, the logPeff values
correlate extremely well with the experimentally measured
parameters. Comparison of the logPeff values for the full
sample set of 12 compounds against their experimental
logBB values gives an excellent correlation coefficient of
R2 ¼ 0.94. Comparison against the available experimental
logPS values also gives an excellent correlation coefficient
of R2 ¼ 0.90, although only over the subset of eight data
points for which logPS data are available.
Thus, by adapting the equation for the linear regression
line between logPeff and logBB (Fig. 5), we propose an
equation to predict the logBB of a compound from its calcu-
lated logPeff,
logBB ¼ logPeff  0:1725
2:808
; (7)
The resulting predicted logBB values (Table 1) are, on
average, <0.2 log units from their experimental values.
This methodology therefore enables a quantitative, accurate
predictive technique using MD simulation for compounds
for which experimental logBB measurements have not yet
been performed.DISCUSSION
Predictive capability
We have demonstrated that our first proof-of-principle
in silico protocol has the potential to accurately predict
the passive permeability of 12 small compounds. Our logPeff
predictions are correlated with logBB and logPS with R2
values of 0.94 and 0.90, respectively, and are comparable
to the commonly used in silico and in vitro prediction
methods.
Frequently, the logP (the octanol/water partitioning
coefficient—a measure of lipophilicity) of a compound
can be used as a quick and simple prediction of its perme-
ability and can be either measured or calculated. Regularly,
logP is one of the best single descriptors in QSAR models.
For a quick comparison of predictive capabilities, the logP
of our 12 small molecules were calculated using a popular
on-line logP prediction server (www.molinspiration.com).
These calculated logP values correlate extremely well
with the experimental logP values (0.95), and have an R2
correlation of 0.81 against logBB, and 0.76 against logPS.
However, when using the actual experimental logP values,
the R2 correlations for these experimental logP values
against experimental logBB and logPS values are only
0.77 and 0.70. Thus, our methodology offers a marked
improvement over this oft-used approximation, as there ap-
pears to be certain crucial parameters missing from the logP
value that are needed to more accurately predict perme-
ability. The in silico prediction of logP values is extremely
Prediction of BBB Permeability 637accurate, but even if the logP prediction was 100% accurate,
the single logP descriptor is not enough to predict BBB
permeability with any correlation better than ~0.75.
Thus, using a single logP descriptor may simply not
be enough to predict BBB permeability. To include more
descriptors, QSAR models are most frequently used. The
equivalent first proof-of-principle in silico protocol for
using a QSAR model to predict logBB was constructed in
1988. It consisted of 20 training compounds and had a cor-
relation of R2 ¼ 0.69 (92). Since that time, the predictive
capabilities of QSAR models have greatly improved. Cor-
relation values of 0.72–0.86 (30–33) against logBB are
the typical range of recent QSAR models. Predicting logPS
using QSAR models generally correlates slightly better,
with typical values of 0.74–0.95 (29,93–95). Recent
comparative QSAR studies (33,97) on a test set of 24 com-
pounds produced predicted logBB values that were both an
average of 0.46 log units from the experimental values,
more than double the 0.20 differential calculated for our
12 compounds. Indeed, even their top 12 closest matching
predictions still had an average difference of 0.22 and
0.26 log units. Despite the success of QSAR models, they
inherently depend on an adequate training set. In other
words, data for similar compounds or compounds that
occupy similar regions of the descriptor space are needed
to train the initial model. Furthermore, the QSAR modeling
approach requires a high quality data set of biological end-
points. Thus, QSAR prediction models depend greatly on
the availability of experimental outcomes, and can only
be considered accurate when the compound of interest
has a common pharmacophore with the compounds in the
training set (96). These biological endpoints and experi-
mental outcomes may not be available for a novel com-
pound of interest, especially when screening new lead
compounds in drug discovery. The approach we present
here is not limited by training sets or available experimental
outcomes. Our approach simply needs the chemical struc-
ture of the compound to yield predictive results, allowing
for any novel compound to be simulated during the drug
discovery process, a clear advantage.
Although the protocol presented here is an in silico
methodology, this in silico approach appears to yield better
correlations than some common in vitro assays. Recently,
permeabilities determined in PAMPA assays were compared
against in vivo logBB values with correlations in the 0.65–
0.75 range (19,22). In addition, R2 correlations for IAM re-
sults against logBB have also reached as high as 0.75 (98).
These methods are resource intensive and slower throughput
than most in silico methods. Our approach has the advantage
of higher throughput than the traditional in vitro methods,
while maintaining comparable (if not better) predictive
capabilities.
Due to the highly expensive, time-consuming methods
needed to gather accurate in vivo BBB permeability data
for new compounds, the method presented here is a reason-able predictive tool to be used in drug design process
because it is faster and cheaper and, most importantly, pre-
dictive of permeability. Inserting a new tool into the early
phase of the drug design process allows better decisions to
be made, regarding which candidate compounds merit
further investigation and could avoid unwanted side effects
in future clinical trials.Robustness of method
Our in silico approach appears to be robust with respect to
possible errors in calculating the PMF near the lipid bilayer
center—a phenomena recently suggested by Neale, et al.
that can often arise due to inadequate umbrella sampling
in this region (99). This inadequate sampling, or hidden
sampling barrier, at the center of the bilayer is caused by
rare conformational transitions between lipid defects, and
can lead to autocorrelation times on the order of 10 ms as
the simulation windows get within 0.5 nm of the bilayer
center (99).
Thus, the uncertainty of the free-energy value at this cen-
tral bilayer section is higher, and using a single free-energy
point at this region as a metric may contain inherent errors.
This may be a potential problem for several recent system-
atic PMF studies that have made quantitative predictions by
taking only a single DG free-energy difference between
two points on the PMF curve, such as DGwater/lipid tails
(100), or between water and another point near the bilayer
center (101).
Similar problems could have occurred in our system if we
had adopted the same approach. For example, consider the
PMF profiles of two compounds we investigated, theophyl-
line (BBB) and nordazepam (BBBþ) (Fig. 3 B, Fig. 6). If
we were to simply take the z ¼ 0 free-energy value as our
criterion for determining BBB permeability, these two com-
pounds, which have experimental permeabilities almost an
entire log unit apart, would then be separated by only
~4 kcal/mol. Furthermore, this value is taken from a region
of high uncertainty, thus leaving little room for error. How-
ever, by implementing our methodology to calculate Peff
(and using it as our measurement criterion), these two com-
pounds are separated by three log units (0.94 and 2.04 for
theophylline and nordazepam, respectively).
To further investigate the robustness of our methodology
to this potential sampling problem, we generated two artifi-
cial PMF profiles. We took the profiles for theophylline (a
BBB compound with a positive free energy at z ¼ 0)
and nordazepam (a BBBþ compound with a negative free
energy at z ¼ 0) and manipulated the height of the energy
barriers at z ¼ 0. The energy barriers were altered by 1.0,
0.5, 0.5, and 1.0 kcal/mol, and these changes in the
PMF profile were extended out to almost z ¼ 0.5 (Fig. 6).
The artificial PMFs simulate potential error in the region
of the central bilayer. Using these newly generated energy
landscapes, various revised logPeff values can be calculated.Biophysical Journal 107(3) 630–641
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FIGURE 6 The artificially adjusted PMF profiles for theophylline (top)
and nordazepam (bottom) and the resulting changes to the correlations
with experimental data (inset).
638 Carpenter et al.After altering the z ¼ 0 energy barriers for each of the nor-
dazepam and theophylline PMF curves, in only one extreme
case does the rank order of the compounds (in terms of their
Peff) change (and only by one position). The correlations
with the experimental logBB results remain completely un-
affected. At most the correlations with logPS are reduced by
only 0.02. Even if we take the combination of the extreme
values, whereby the nordazepam PMF was increased by
1 kcal/mol and the theophylline PMF was reduced by
1 kcal/mol, the R2 correlations with logBB and logPS are
still 0.94 and 0.91, respectively. The advantage of our meth-
odology is that it uses the entire PMF energy landscape.
Thus, although the free-energy value at the bilayer center
is still important, it does not carry the critical weight that
it does for single-point measurements.
A further test of the robustness of the methodology is the
selection of the cutoff value between what is classified as
membrane and bulk solvent. Only within-membrane values
of diffusion and PMF free energies are used to calculate the
membrane Peff. Given that the density of the DOPC lipid
reaches zero at z ¼ 3.0 nm, and all the PMF curve values
are zero (or very close to zero) at z ¼ 3.0 nm, this valueBiophysical Journal 107(3) 630–641was the logical choice for the cutoff limit. However, the
possibility remains that the chosen value may be too low
or too high, and our model may be sensitive to an unsuitable
cutoff. The use of an unsuitable cutoff value could result in
inaccurate results due to either information being excluded
(cutoff too low) or the inclusion of bulk-water artifacts
(cutoff too high). To assess the effect of the cutoff value
on our results, the Peff for each compound was calculated us-
ing cutoffs of 2.5 and 3.5 nm, and the data again correlated
against experiment. The 2.5 nm cutoff resulted in R2 corre-
lations with logBB and logPS of 0.96 and 0.89, although
equivalently the 3.5 nm cutoff correlations were 0.93 and
0.92. Thus, the methodology is insensitive to these varia-
tions in the membrane width cutoff value.Limitations
Despite the encouraging success of our system in predicting
correlation against experimental values, the model has some
limitations that should be noted. As with some simple
in vitro methods (such as PAMPA and IAM), our system
does not account for nonpassive compound movement of
any sort. Thus, the model does not take into consideration
the effect on any compounds that are subject to either
P-gp-mediated efflux back across the BBB, or active uptake
systems. For proof-of-principle testing and calibration, this
limitation is less of an issue, as compounds can be selected
based upon their purely passive permeability properties.
However, for the ultimate goal of BBB permeability predic-
tion of novel compounds this is a more important consider-
ation. We foresee the future possibility of combining our
in silico approach with additional in silico methods, such
as docking the compounds to efflux/influx protein models,
to determine a permeability profile that takes into account
the active transportation routes.
Another possible limitation of our system is that for the
sake of simplicity we have only included a single type of
lipid in our membrane. The use of a mixed-lipid system
would require a much longer equilibration time and thus
an increased computational burden. Mixed-lipid simulations
have a much shallower depth of literature, thus comparison
and validation of our results would have proved more
difficult.
Furthermore, other PAMPA models actually found better
correlation when using a simple Black Lipid Membrane (a
pure DOPC bilayer) instead of a bilayer representative of
brain endothelial cells, although differences were minimal
(19). Additionally, studies using a single type of lipid/deter-
gent have achieved a R2 correlation of 0.75 and 0.79 using
IAM and MLC (micellar liquid chromatography), respec-
tively (98). Thus, our system agrees with several in vitro
models that suggest a simple, single lipid membrane model
can be sufficient to predict BBB permeability.
There are also a couple of computational difficulties to
consider. We acknowledge that the quality of the force field
Prediction of BBB Permeability 639that is used to carry out the simulations and build high
quality all-atom models for each molecule is a limitation.
Different MD force fields have different strengths and weak-
nesses, and using one force field over another may result in
slightly varied results (102). Using different methodologies
to assign partial charges on compounds can also lead to
varied results (68).
Finally, we must consider the computational cost of
carrying out the free-energy calculations. Although each
compound took an average of 150,000 cpu hours to generate
a PMF and permeability value, the resulting values are
extremely well correlated to experimental values (>0.90).
Calculating logP values is indeed computationally cheap
(magnitudes less than PMF calculations). However, the
logP values are inherently lacking sufficient information
and at best give correlations to experiment of 0.75. Given
the expense of late stage failures in drug development, the
added computational cost of using PMFs to predict perme-
ability may be well worth the price. Furthermore, with in-
creases in computing power and parallelization, the actual
time to complete these measurements will only continue
to decrease.CONCLUSIONS
We have demonstrated success of our in silico BBB
permeability prediction method using a small but diverse
data set. This proof-of-principle study is similar in size
to one of the earliest pioneering QSAR models to predict
BBB permeability that was built in 1988 (training set of
20 compounds) (92). This early QSAR model only had
an R2 correlation of 0.69 with experimental data. Our
methodology is correct in qualitatively predicting 11 of
12 compounds to be either BBBþ or BBB, and also es-
tablishing 10 of 12 in the exact order in terms of their
experimentally measured permeability. Furthermore, we
have quantitatively compared our results with the two ma-
jor in vivo measures of BBB permeability: logBB and
logPS. Our results have an R2 correlation of 0.94 and
0.90 with logBB and logPS, respectively—values that
are comparable to or better than those of other prediction
models. On average, our calculated logBB numbers were
within 0.2 log units of their experimental values—again,
comparable to or better than other prediction models.
Thus, we have established the potential of this methodol-
ogy to be expanded and developed in the future. Perhaps
ultimately an in silico method similar to ours may be
used in drug discovery as an accurate, relatively fast
BBB permeability prediction tool, which does not rely
upon (nor is biased by) existing data.SUPPORTING MATERIAL
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